PGNY logo

Progyny Inc. (PGNY)

$36.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PGNY

Market cap

$2.66B

EPS

1.09

P/E ratio

30.3

Price to sales

1.63

Dividend yield

--

Beta

0.971585

Price on PGNY

Previous close

$36.58

Today's open

$36.74

Day's range

$36.08 - $36.76

52 week range

$16.10 - $37.16

Profile about PGNY

CEO

Peter Anevski

Employees

856

Headquarters

New York, NY

Exchange

Nasdaq Global Select

Shares outstanding

73647334

Issue type

Common Stock

PGNY industries and sectors

Healthcare

Healthcare Providers & Services

News on PGNY

Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know

Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • 6 hours ago

news preview

Progyny: 3 Key Takeaways for Long-Term Investors

Progyny added 1.3 million covered lives for the 2027 plan year. Progyny achieved a near 100% pharmacy attach rate with new clients.

news source

The Motley Fool • Nov 11, 2026

news preview

Fertility Treatment Leader Progyny Breaks Out Past Buy Point As Earnings Surge 113%

Progyny stock broke out past its latest buy point after the company's Q3 earnings surged 113% vs. year-ago period.

news source

Investors Business Daily • Nov 9, 2026

news preview

Progyny Q3 Earnings Call Highlights

Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.

news source

MarketBeat • Nov 5, 2026

news preview

Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript

Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Progyny, Inc. Announces Third Quarter 2026 Results

Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guidance Ranges NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2026 (“the third quarter of 2026”), as compared to the three-month period ended September 30, 2025 (“the third quarter of 2025” or “the prior year period”). “We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients,” said Pete Anevski, Chief Executive Officer of Progyny.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates

Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits

Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care

news source

GlobeNewsWire • Oct 28, 2026

news preview

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.

news source

GlobeNewsWire • Oct 21, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Progyny Inc.

Open an M1 investment account to buy and sell Progyny Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PGNY on M1